TScan Therapeutics Inc
For the period ended Dec 31, 2024. Filed Mar 5, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 5, 2025
TCRX$0.19+2.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
(in thousands, except share data and issuance costs)
| Additional · AccumulatedOther · Total | ||||||||
|---|---|---|---|---|---|---|---|---|
| Voting Common Stock · Non-voting Common Stock · Paid-In · Comprehensive · Accumulated · Stockholders’ | ||||||||
| Shares | Amount | Shares | Amount | Capital | Loss | Deficit | Equity | |
| Balances at January 1, 2023 | 19,082,820 | 2 | 5,143,134 | 1 | 257,810 | - | (158,379) | 99,434 |
| Exercise of stock options | 316,441 | - | - | - | 711 | - | - | 711 |
| Issuance of common stock, net of offering costs | 23,287,134 | 2 | - | - | 42,412 | - | - | 42,414 |
| Issuance of pre-funded warrants, net of offering costs | - | - | - | - | 92,318 | - | - | 92,318 |
| Conversion of non-voting common stock to voting common stock | 866,546 | - | (866,546) | - | - | - | - | - |
| Stock-based compensation expense | - | - | - | - | 5,208 | - | - | 5,208 |
| Net loss | - | - | - | - | - | - | (89,218) | (89,218) |
| Balances at December 31, 2023 | 43,552,941 | 4 | 4,276,588 | 1 | 398,459 | - | (247,597) | 150,867 |
| Exercise of stock options | 586,081 | - | - | - | 1,717 | - | - | 1,717 |
| Issuance of common stock under employee stock purchase plan | 82,153 | - | - | - | 333 | - | - | 333 |
| Issuance of common stock, net of offering costs | 4,958,068 | 1 | - | - | 33,130 | - | - | 33,131 |
| Issuance of pre-funded warrants, net of offering costs | - | - | - | - | 158,071 | - | - | 158,071 |
| Conversion of convertible debt | 3,134,796 | - | - | - | 14,750 | - | - | 14,750 |
| Stock-based compensation expense | - | - | - | - | 9,549 | - | - | 9,549 |
| Net loss | - | - | - | - | - | - | (127,499) | (127,499) |
| Unrealized gain on available-for-sale securities | - | - | - | - | - | 51 | - | 51 |
| Balances at December 31, 2024 | 52,314,039 | $5 | 4,276,588 | $1 | $616,009 | $51 | $(375,096) | $240,970 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.